No matches
Dermatology

Expert Interview with Dr Jason Hawkes

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.
Jason Hawkes
MD, MS
Jason Hawkes

Learning objectives

  • Highlight potential roles of cytokine and immune cell dysfunction in CSU pathogenesis including mast cell activation and how it impacts patients QoL
Tags
mast cellsdisease backgroundexpert insightssymptomsIL-4IL-13type 2 inflammation
MAT-GLB-2503463 - 1.0 - 07/2025

About this expert

Dermatology

Jason Hawkes

MD, MS

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

See author’s profile
Jason Hawkes

Related resources

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

AD and PN: Commonalities and Differences – A Case Study
Dermatology
expert video

AD and PN: Commonalities and Differences – A Case Study

Can Emerging Treatments Help Address Individual PN Patient Burden?
Dermatology
expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

Differences in Manifestations of Type 2 Inflammatory Diseases
Dermatology
expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

Emerging Therapeutic Landscape and Implications for Patient Management in CSU
Dermatology
expert video

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management
Dermatology
expert video

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

Mast Cells and the Neuroimmune Axis in CSU
Dermatology
expert video

Mast Cells and the Neuroimmune Axis in CSU

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions
Dermatology
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
Dermatology
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

How Should We Define and Classify Prurigo Nodularis?
Dermatology
expert video

How Should We Define and Classify Prurigo Nodularis?

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

Type 2 Inflammation Modulates the Neuroimmune Axis in PN
Dermatology
expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis
Dermatology
expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology
Dermatology
expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

Type 2 Inflammation Alters the Structure and Function of the Skin in AD
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Exploring Neurosensitization and Pain in Prurigo Nodularis
Dermatology
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis
Dermatology
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

What is Early Intervention in AD?
Dermatology
expert video

What is Early Intervention in AD?

Disease Modification in AD
Dermatology
expert video

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin
Dermatology
expert video

Systemic Inflammation in AD – Beyond the Skin

Dysbiosis, Skin Infections, and Itch
Dermatology
expert video

Dysbiosis, Skin Infections, and Itch

Skin Barrier Dysfunction in AD
Dermatology
expert video

Skin Barrier Dysfunction in AD

Early Intervention and the Potential for Disease Modification in Children With AD
Dermatology
expert video

Early Intervention and the Potential for Disease Modification in Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD
Dermatology
expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
Dermatology
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

Skin Dysbiosis in AD
Dermatology
expert video

Skin Dysbiosis in AD

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch
Dermatology
expert video

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

The Impact of Skin Dysbiosis on Atopic Dermatitis
Dermatology
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD
Dermatology
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers
Dermatology
expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

Barrier Tight Junction Disruption in Atopic Dermatitis
Dermatology
expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 

The Burden of Atopic Dermatitis in Children – Bullying in School
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Bullying in School

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

The Role of Epithelial Barrier Components in AD: Insights and Implications
Dermatology
expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD
Dermatology
expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

The Potential Impact of Early Intervention in Atopic Dermatitis in Children
Dermatology
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
Dermatology
expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

Managing Injection Pain in Children
Dermatology
expert video

Managing Injection Pain in Children

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN
Dermatology
expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

Key Type 2 Cytokines Impact Skin Structural Proteins in Atopic Dermatitis
Dermatology
expert video

Key Type 2 Cytokines Impact Skin Structural Proteins in Atopic Dermatitis

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis
Dermatology
expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

The Role of Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FinlandChange country/region